Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493339 | 0.82 | SMN1; SMN2 (0.50) | HRH4 | |
| SCHEMBL19924700 | 0.81 | SMN1; SMN2 (0.53) | HRH4 | |
| SCHEMBL922909 | 0.78 | KMT2A (0.49) | — | |
| Hydrochloric Acid SCHEMBL925122 | 0.76 | KMT2A (0.47) | — | |
| SCHEMBL25429453 | 0.71 | RAB9A (0.72) | HRH4HRH3HTR3A | |
| SCHEMBL14487064 | 0.71 | HRH4 (0.50) | HRH4HTR3A | |
| SCHEMBL2167266 | 0.71 | HRH4 (0.89) | HRH4HRH3 | |
| SCHEMBL5005488 | 0.71 | HRH4 (0.65) | HRH4HRH3HTR3A | |
| SCHEMBL1493333 | 0.70 | ADRA2C (0.55) | — | |
| SCHEMBL13212601 | 0.69 | KDM4E (0.52) | HRH4HRH3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110062758-B | Bicyclic dihydropyrimidine-carboxamide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-01-17 | — | — | CN | disclosed |
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-03-10 | — | — | US | disclosed |
| CN-110062758-A | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 奇斯药制品公司 | 2019-07-26 | — | — | CN | disclosed |
| WO-2018115383-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| CN-101405289-A | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH CORP (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| CN-1671379-A | Hydrazinopyrazole derivatives and their use as therapeutic agents | QUADRA LOGIC TECH INC (CA) | 2005-09-21 | — | — | CN | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | HRH4 551/4885HRH3 668/4885HTR3A 4072/4885 |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | HRH4 1029/4885HRH3 2123/4885HTR3A 2839/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | HRH4 1029/4885HRH3 2123/4885HTR3A 2839/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | HRH4 3588/4885HRH3 3362/4885HTR3A 3021/4885 |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, TYMP, TYMS | HRH4 2746/4885HRH3 3245/4885HTR3A 1037/4885 |
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | HRH4 551/4885HRH3 668/4885HTR3A 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.